Compounded tirzepatide, the next step in GLP-1 therapy.

On weight loss alone, head-to-head trials favor tirzepatide at the higher doses. SURMOUNT-5, published in 2025, compared the two directly and confirmed a significant advantage for tirzepatide on weight outcomes. That doesn’t make it automatically the right choice for everyone. Semaglutide is usually the first-line option and the more studied of the two, and cost, side-effect profile, and how your body handles dual-receptor therapy all matter. Tirzepatide tends to be the better pick if your BMI is over 35, you have significant insulin resistance, you have a history of PCOS with metabolic features, or you haven’t reached your goal on semaglutide alone. We often start patients on semaglutide, optimize for four to six months, and switch only if progress plateaus. We’ll walk through the trade-offs at your visit.

The active molecule is the same. Mounjaro, for type 2 diabetes, and Zepbound, for weight loss, are Eli Lilly’s brand versions. What we prescribe is a compounded version of that same active molecule, prepared by a licensed US 503A compounding pharmacy, at a significantly lower cost. The difference is price and sourcing, not pharmacology. Our titration follows the published SURMOUNT trial schedule, so your dose steps match what the research used rather than something improvised. Dr. Oliver Morris writes the prescription after an in-person consult and baseline labs, then adjusts at monthly follow-up based on how you respond. For cost context, Zepbound at pharmacy retail without insurance runs roughly $1,000 or more per month. Compounded GLP-1/GIP medications are self-pay, and we quote exact numbers at your consultation.

GI side effects lead the list: nausea, reflux, constipation, and occasional diarrhea. They’re almost always dose-related and improve with slower titration, steady hydration, and smaller protein-forward meals. Less commonly we watch for gallbladder issues, pancreatitis, and thyroid concerns, which is the reason we run baseline labs covering A1c, thyroid, kidney, liver, and lipids, then recheck as needed at your monthly visits. Tirzepatide isn’t prescribed if you or a family member has a history of medullary thyroid cancer or MEN2, if you have active pancreatitis or severe GI disease, or if you’re pregnant or breastfeeding. Tell Dr. Oliver Morris what you’re actually feeling at each follow-up. Most side effects stay manageable when the dose is matched to your tolerance instead of a default schedule.

Appetite typically drops within the first two weeks, before the scale moves much. Visible weight loss usually starts around week four and accelerates as the dose climbs. The starting dose is 2.5 mg weekly for the first four weeks, which is the tolerance-building phase, then 5 mg for weeks five through eight, where most patients begin seeing 2 to 5 lbs per week. If you’re tolerating it, the dose moves to 7.5 mg around week nine, and we repeat a brief lab panel and check body composition to confirm you’re losing fat rather than muscle. Expect the biggest changes between month three and month nine. From month four onward most patients stabilize between 7.5 and 12.5 mg depending on goals and tolerance, and a subset reach 15 mg.

Yes, and it’s a common path. We review your current labs and dose, then start tirzepatide at a titration that fits where you are. Most patients cross over without a washout period. The usual reason to switch is a plateau. We often start patients on semaglutide, optimize for four to six months, and move to tirzepatide only if progress stalls, since that sequencing tends to be kinder on the GI side and saves money for people who respond well to a single agonist. Tirzepatide also tends to be the better fit at a BMI over 35, with significant insulin resistance, or with a history of PCOS with metabolic features. Dr. Oliver Morris reviews your history in person and writes the new titration plan before you make the change.

Compounded GLP-1/GIP medications are self-pay. Because the program is self-pay, there’s no prior authorization to chase and no coverage denial to appeal. For context, most patients find our program cost is meaningfully less than the out-of-pocket cost of Zepbound if insurance denies it, and Zepbound at pharmacy retail runs roughly $1,000 or more per month. HSA and FSA reimbursement is usually eligible, and we support CareCredit. Your monthly cost depends on your dose and includes the compounded medication, supplies, and your monthly follow-up visit. Baseline labs are billed separately at wholesale. We don’t publish a single number because dose and duration differ by patient, so we quote exact figures at your consultation for the full expected treatment window rather than a teaser monthly rate.

Like any rapid weight loss, a portion of what you lose can be lean mass. We plan around that from the start. The protein target is 0.8 to 1.0 g per pound of goal weight, resistance training two to three times per week, and body composition measured at your visits so we catch muscle loss before it becomes significant. Around weeks nine to twelve we reassess body composition specifically to confirm you’re losing fat rather than muscle, and if the numbers move the wrong way we adjust rather than push the dose higher. Appetite suppression makes protein the easy thing to skip, since total intake drops, so hitting the target takes deliberate effort. Holding a lower weight with lean mass preserved is the outcome that actually lasts.

Moderate alcohol is fine for most patients. Delayed gastric emptying can intensify the effect of alcohol, so expect to feel it faster and to feel it longer than you’re used to. Our recommendation is to dial back initially and see how you respond rather than assume your old tolerance still applies. The practical version: cut your usual amount, drink water alongside it, and don’t test it for the first time on the same day as a dose increase. If you’re in a week where nausea or reflux is already bothering you, that’s a reasonable week to skip it. Bring it up at your monthly visit if drinking is a regular part of your social life, so it’s part of the conversation instead of a surprise.

Without a taper and a maintenance plan, most patients regain significant weight within six to twelve months. That’s why we build the exit plan at the start rather than at the end: a slow taper, a maintenance dose for many patients, and intentional lifestyle anchors that hold once the medication comes down. In practice those anchors are protein, resistance training, and consistent sleep, because appetite regulation gets harder when any of them slips. Some patients stay on a low maintenance dose indefinitely. Others come off entirely once their habits are established. That decision happens at a clinical checkpoint with Dr. Oliver Morris, based on your weight trend, your labs, and how durable your routine looks, not on a fixed calendar.

Dr. Oliver Morris is the prescribing physician at Olympia Aesthetics & Wellness, and you see him at every visit. He’s a board-certified physician and the practice’s medical director, and he handles the whole arc of care: the initial in-person consult, baseline labs covering A1c, thyroid, kidney, liver, and lipids, the titration plan, and monthly follow-up at our Palm Harbor clinic. This is not a telehealth questionnaire with a rotating prescriber signing off on a dose. Dose changes come from how you’re actually responding, reviewed in person. You can read his background on the Dr. Oliver Morris bio page. If you have questions before committing to anything, the consult is the place to ask them, and we decide together whether tirzepatide is the right fit.